Join
Live feed
·
PRReleasevia Quantisnow
Mersana Therapeutics Inc. logo

Mersana Therapeutics to Provide Update on the Progress of its UpRi Clinical Development Strategy and Report Interim Data from the Ovarian Cancer Expansion Cohort of the UpRi Phase I Study

ByQuantisnow·Wall Street's wire, on your screen.
MRSN· Mersana Therapeutics Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track MRSN (Mersana Therapeutics Inc.) and more on Quantisnow.